Geoffrey Block, MD
Gastroenterology · Rancho Mirage, CANPI 1942208608
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.1%), consulting fees and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 66.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,957 and has fallen 84.0% since, to $314 in 2025.
Across 38 payments — averaging $82.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- AbbVie$409
- Mallinckrodt Hospital Products Inc.$147
- Novo Nordisk$118
- Ipsen Biopharmaceuticals, Inc$94
- Cook Medical LLC$67
- plus $225 from 5 others
Across 62 payments — averaging $5234.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$325K
What the payments were for
- Consulting fees$1,50048%
- Food & beverage$1,60151%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $2,073 |
| AbbVie | 16 | $409 |
| Mallinckrodt Hospital Products Inc. | 1 | $147 |
| Novo Nordisk | 1 | $118 |
| Ipsen Biopharmaceuticals, Inc | 1 | $94 |
| Cook Medical LLC | 1 | $67 |
| Madrigal Pharmaceuticals | 2 | $62 |
| Olympus America Inc. | 1 | $55 |
| Pfizer | 3 | $47 |
| Isoray, Inc | 1 | $40 |
| Shionogi Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HABIB ENDOHPB$1,500
- TERLIVAZ$147
- GENERAL - THERAPIES$125
- Mavyret$124
- Wegovy$118
How this compares
$3,134 in reported general payments places this provider in the 55th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 27 | $2,048 |
| Ursodiol | 13 | $1,121 |
| Fluconazole | 17 | $357 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $341 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $268 |
| Fludrocortisone Acetate | 11 | $122 |
| Furosemide | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Rancho Mirage
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
- Kenneth BinmoellerSan Francisco$507K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.